Fundraising Fox
Protego Biopharma
San Diego, US · Delaware corporation · 28 employees on LinkedIn · 8 known investors
Find your way into Protego Biopharma
102 people in our graph can introduce you to the Protego Biopharma team.
Sign up to see every warm intro you have to Protego Biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Protego Biopharma team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.
Founders & leadership
Board
Investors · 8
How we know: Droia Ventures's portfolio page · funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: Novartis Venture Fund's portfolio page · funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$85M disclosed across 3 of 5 rounds · 2019–2025
- Undisclosed amountseries BDec 2025Source ↗
▶$32.9MraisedDec 2025 · 18 investors · Other Health CareRule 506(b)
- TIM LOHOFFDirector
- EDWARD HURWITZDirector
- HANK MICHAEL PETRASSIExecutive Officer
- JANWILLEM NAESENSDirector
- SAOUSSEN BEN HALIMADirector
- LAURA BRASSDirector
- JEFFERY KELLYDirector
- Brent J. WarnerExecutive Officer, Director
- SHELLEY CHUDirector
- HELEN KIMDirector
- Offering amount
- $130.4M
- Amount sold
- $32.9M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$51MraisedOct 2021 · 6 investors · BiotechnologyRule 506(b)
- Richard LabaudiniereExecutive Officer, Director
- Jeffrey KellyDirector
- Edward HurwitzDirector
- Shelley ChuDirector
- Helen KimDirector
- Offering amount
- $51M
- Amount sold
- $51M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedDec 2019 · 3 investors · BiotechnologyRule 506(b)
- XIN JIANGExecutive Officer
- Edward HurwitzDirector
- Jeffery W KellyPromoter
- Richard LabaudiniereDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Protego Biopharma.
In the news
Frequently asked questions
- What does Protego Biopharma do?
- Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.
- Who are Protego Biopharma's investors?
- Protego Biopharma's investors include Droia Ventures, Novartis Venture Fund, Digitalis Ventures, Forbion, Lightspeed Venture Partners, MPM BioImpact, Vida Ventures, YK Bioventures.
- How much funding has Protego Biopharma raised?
- Protego Biopharma has disclosed $85M raised across 3 of its 5 known rounds.
- Where is Protego Biopharma headquartered?
- Protego Biopharma is headquartered in San Diego, US.